

# Index

## A

- Accelerated partial breast irradiation (APBI), 151–170, 203–216
- Accepted conformance, 256
- AccuBoost, 419–429
  - chest wall applicators, 426
  - dosimetry, 423–425
  - image guidance, 420–422
  - margin directed treatment, 425–426
  - patient selection, 425
  - skin flash, 427, 428
- AlignRT system, 320–321
- American Brachytherapy Society, 6, 11
- American Society of Breast Surgeons (ASBrS), 6, 11, 258–260
- Anesthesia, 192, 225
  - conscious sedation, 229
  - general, 229
  - local, 229, 231, 241
- Anisotropy, 254–256
- Applicator–skin distance, 249, 256
- Appropriateness of application, 109–110
- Augmentation, 226, 229

## B

- Bacitracin ointment, 238
- Balloon ruptures, 247, 249–251, 253–257
- Balloon breast brachytherapy applicator, 247, 259
- Balloon–cavity conformance, 249
- Balloon device, 61
  - conformance, 65
  - symmetry, 67–70
- Balloon intracavitary brachytherapy, 223, 224, 243
- Balloon–skin distance, 249
- Biological effective dose (BED), 48, 269, 378
- Biological equivalent dose (BED), 11–12
- Brachytherapy, 219–245
  - dose, 219–222, 224–227, 229, 239–244
  - future, 223, 233, 244, 245

- selection criteria, 221, 243, 244
- vs. external beam techniques, 242, 244
- Breast cancer, local treatment, 327–329
- Breast conservation therapy (BCT), 203
- Breast multidisciplinary conference, 244
- Breast toxicities
  - edema, 213
  - erythema, 213
  - fat necrosis, 213, 214
  - fibrosis, 213, 214
  - hyperpigmentation, 213, 214
  - hypopigmentation, 213, 214
  - pain, 213
  - telangiectasia, 213, 214

## C

- Catheters, 219–221, 224–226, 229, 231–232, 237–239, 241–243
  - buttons, hemispheric, 237, 239
  - Comfort (R) catheters, 237–238
  - extra superficial, 226, 237
  - insertion, 220, 225–242
    - prepping, draping, and mastisol, 232
  - multi-catheter
    - care, 197
    - placement, 189, 190, 192–201
  - separation
    - LDR (again), 220
    - Ochsner Clinic-Phase II Trial, 220
- Cavity contouring, 235
- Cavity definition
  - contrast, 231
  - CT, 231
  - ultrasound, 231
- Cavity evaluation device (CED), 254
- Checking the lengths, catheters or catheter inserts, 106–108
- Chemotherapy, 73, 389, 391
- Christie Hospital trial, 278, 280
- ClearPath, 62, 68, 86–87, 400–402, 405–406

- Clinical target volume (CTV), 35, 37, 39, 41, 43, 268, 272, 274
- Closed technique, 249
- Cone beam computed tomography (CBCT), 307, 309–310
- Cone-beam CT scan, 295–296
- 3D Conformal, 28
- APBI delivery modalities
    - IMRT, 283
    - proton therapy, 283–284
    - radiosurgery, 284
    - tomotherapy, 283
  - external beam, 391–392
  - PBI
    - breathing motion and set-up uncertainty, 223, 224
    - dose per fraction, 224, 244
    - exit dose to other organs, 224
    - fibrosis, 224
    - issues and concerns, 242
- Conformality index (CI), 112–113
- Conformance, 249, 253, 256
- Contrast injection, lumpectomy cavity, 230
- Contura, 85–86, 91, 241–243, 400, 401, 405
- rotation, 242
- Contura MLB, 215
- Cosmetic outcome, 213–215
- Cosmetic results, 154, 158, 160, 163, 166
- CT guidance, 76–77, 190, 199
- CT simulator, 191
- D**
- $D_{90}$ , 250, 256, 257
- Dose homogeneity, 224, 244, 250
- Dose homogeneity index (DHI), 53–54, 240, 379, 380, 383–385
- Dose optimization, 78–79, 240
- Dose–volume histogram (DVH), 267, 272
- Dosimetric characteristics, 379
- Dosimetric guidelines (multi-catheter), 197–199
- Ductal carcinoma, 272
- Ductal carcinoma in situ (DCIS), 1–2, 11, 126, 127, 131–134, 136–138, 141–142, 259
- Dwell time
  - function of distance, 116
  - function of volume, 114–115
- E**
- Early Breast Cancer Collaborative Trialists' Group, 1, 7
- Early-stage breast cancer, 263, 274
- EBRT. *See* External-beam radiotherapy
- Electron beam PBI, 224–225
- intraoperative electrons, 225
- Electronic brachytherapy, 88–94, 410–419
- beam directionality, 418, 419
  - clinical experience, 414, 418–419
  - depth-dose modulation (DDM), 418
  - dose to bone, 414–416
  - dosimetry, 411–414
  - radiobiology
    - linear energy transfer (LET), 414, 415
    - photoelectric effect, 414–416
    - relative biologic effectiveness (RBE), 414, 415
    - source anisotropy, 416–418
    - variable energy, 418
- Elliptical balloon, 251, 253, 255–256
- Elsewhere failures, 22
- Equivalent uniform dose (EUD), 54
- Evaluating adequacy, plan, 121–122
- Exposure rate, 264, 272
- External beam, 95–99
- External beam accelerated partial breast irradiation, 315, 324
- External-beam APBI, 51–52, 142–145
- External-beam PBI, 301–311
- External-beam radiotherapy (EBRT), 331
- trial analysis, 338–339
  - vs. IORT, 333
- F**
- Fat necrosis, 158, 160, 161, 163, 380, 381, 383, 384, 389, 391–393
- Fibrosis, 154–155, 158, 163, 166
- Fiducial needle, 265–266, 268–272
- Fractionation schedules, 3D conformal APBI, 282
- Freehand technique, 265–266
- H**
- HAM applicator, 367–368
- Health economics, 339–340
- High dose rate (HDR), 73, 75–79, 379, 380, 382–384, 391, 393
- High dose rate (HDR) brachytherapy, 203
- dose prescription, 211
  - HDR Iridium-192 source, 205
  - template-based, 204, 205
- Homogeneity index, 82–83, 85
- Hypofractionated, 3, 12–14

**I**<sup>125</sup>I, 74, 91IBTR. *See* Ipsilateral breast tumor recurrence

Immobilization, 95, 97–98

In-breast failures, 22–23, 26

Infections, 386, 390

Intensity-modulated radiation therapy (IMRT),  
2, 283

Interstitial, 74–79, 83, 85

Interstitial brachytherapy, 127, 129–131, 135,  
140, 141, 145, 151, 156, 158,  
220, 223, 241, 243–244, 377,  
378, 380–385, 390, 393

in augmented breasts, 226

catheter spacing, 226

clinical data, 126, 133

crossing catheters, 226, 227

deep catheters below template, 237

freehand technique, 225–226, 229

high dose rate (HDR), 152, 156–158, 160,  
161, 163, 167

history, 224

implants, 205

closed cavity

real-time intraoperative

ultrasound, 210

virtual treatment plan, 210

open cavity, 205–208

Kuske template, 231

low density rate (LDR), 152, 154–157

medium dose rate (MDR), 152, 154,  
155, 157

open cavity insertion, 225–227

prone insertion on stereotactic table,  
229–230pulsed dose rate (PDR), 158, 161,  
163, 167

single plane implants, 226

skin dose, 226

supine CT-guided technique, 231–232

ultrasound-guided, 227–229

Interstitial dosimetry, 78–79

Interstitial implant APBI, 52–54

Interstitial implants, 75–79, 83, 85, 101–104,  
113, 115, 116, 279–280checking the implantation equipment,  
101–102

checking the intracavitary equipment, 104

Interstitial technique, 127–131

Intrabeam, 93–94

homeopathic dose, 225

Intrabeam system, 331, 337–339

advantages, 333

clinical trials, 337–339

machine parts, 335

mathematical model, 332

radiobiological aspects, 331–332

schematic diagram, 336

surgical technique, 337

translational research, 329–330

x-ray source, 332–333

Intracavitary, 79–86, 88

Intracavity brachytherapy, 377, 385–391

Intrafraction movement, 306

Intraoperative, 367–378, 386–393

Intraoperative APBI, 50–51

Intraoperative avidination, 428–429

Intraoperative radiation therapy (IORT), 345,  
367, 368, 370–376

characteristics, 335

partial breast irradiation, 334–335

radiobiology, 331–334

vs. EBRT, 333

Ipsilateral breast tumor recurrence  
(IBTR), 328<sup>192</sup>Ir, 74–75, 81, 89–91, 93**L**

Lateral techniques, 253

LDR implant, 74

Lea-catchside time factor, 331

Length, 106–108, 115–117, 120

Linear quadratic (LQ) equation, 48

Local anesthesia, 229, 231, 241

Local control, PBI

Ochsner clinic results, 220

RTOG 95-17 results, 221, 223

Local freezing, 271

Local recurrence (LR), 151–158, 160, 163,  
164, 167, 169

Location, breast cancer, 64

Loss of heterozygosity (LOH)

assay, 42

Low dose-rate (LDR), 379, 380,

382–384, 391

Low dose rate (LDR) brachytherapy  
implant

dose, 204

I-125 sources, 203–205

template-guided, 204

Lumpectomy, 59–60, 63–67, 69

cavity shape and size, 63–66

oncoplastic technique, 71

technical considerations, 67–71

wire localization, 65–66

Lung constraints, 318

Lymphovascular infiltration, 272

**M**

Magnetic resonance imaging (MRI), 9  
 MammoSite, 28–29, 40–41, 79–85, 91, 224, 240–242, 273, 274, 385–391, 393, 410, 412, 413, 417  
     aborted procedures, 240  
     closed wound insertion, 240  
     dehiscence, 241  
     failure and salvage techniques  
     intraoperative insertion, 240–241  
     lateral trocar insertion, 241  
     SET insertion, 241  
     skin separation issues, 224, 243  
     tissue compression, 243  
     tissue conformance, 241  
 MammoSite balloon, 132  
     clinical results, 141, 142  
     mammosite, 135–142  
 MammoSite balloon brachytherapy, 399, 400  
 MammoSite brachytherapy, 151, 163–166, 169  
 MammoSite RTS, 215, 216, 247, 260, 261  
 MammoSite technique, 54  
 Mamograph/Template, 75–76  
 Margin beyond cavity, 223  
 Massachusetts General Hospital (MGH), 315–325  
     experience, APBI, 284, 294  
 Mastectomy studies, 35–37  
 Matched pair analysis  
     cause-specific survival, 212  
     ipsilateral breast tumor recurrence, 212  
     regional failure, 212  
 Memorial Sloan–Kettering Cancer Center (MSKCC), 367, 368, 370–375  
 Moist desquamation, 273  
 Molecular clonality assay, 212  
 Multicatheter, 28–29  
 Multicatheter interstitial brachytherapy (MIB), 39, 397–399, 404  
 Multifocality, 35  
 Multi-institution registry trial, 258  
 Multiple dwell positions, 251–253, 256

**N**  
 National Council on Radiation Protection (NCRP), 264  
 National Surgical Adjuvant Breast and Bowel Project, 11  
 Needle retraction method, 269  
 Neuroleptanalgesia, 271  
 Noncoplanar beams, 318

NSABP-B 39, 296–298  
 NSABP B-39/RTOG 0413 trial, 216, 221, 302, 307–308

**O**

Ochsner Clinic, 219–220, 222, 224  
     matched pair analysis, 221  
 Open placement, 259

**P**

Pain, 271, 273  
 Palladium-103 (<sup>103</sup>Pd), 264, 269  
 Paradigm shift, 222–223  
 Partial breast irradiation (PBI) method, 221, 222, 224, 263, 274, 301–311, 334–335, 345, 358  
     device selection, 242  
     margins, 245  
     phase III trials, 244  
     rationale, 223  
 Pathology data, 20–21, 27  
 Patient selection, 126–128, 133, 136, 138, 146, 151, 153–156, 169  
 Patient selection criteria, 59–60  
 PCR assay, 43  
<sup>105</sup>Pd, 74  
 PEEK plastic, 265  
 Permanent breast seed implant (PBSI), 263–274, 428  
 Phase III trials, 173–186  
     EIO ELIOT, 174, 175  
     Groupe Europeen de Curietherapie, European Society for Therapeutic Radiology and Oncology (GEC-ESTRO), 174, 176–181, 184, 185  
     NIO Hungarian, 174  
     NSABP B39/RTOG 95-17, 176, 178–180, 182–185  
     randomized trial, accelerated partial breast irradiation (RAPID), 174–176  
     targeted intraoperative radiotherapy trial (TARGIT), 174, 175  
     UK IMPORT low, 174, 175  
 Photon/electron technique, 315, 317, 318  
 Photon radiosurgery system (PRS), 332–333  
 Planning target volume (PTV), 268, 269, 271, 272, 317–319, 322  
     expansion, 316  
     growth, 235  
 Pneumonitis, 50  
 Pneumothorax, 230, 237

- Post-implant CT, 267, 273  
 Post-implant edema, 267  
 Preimplant CT scan, 191  
 Preparing the catheters, imaging, 105–106  
 Prone 3D conformal APBI, 281, 284, 286  
   New York University experience, 286–288  
 Prone position, 301, 304, 306, 307  
 Proton radiation, 315, 322, 323  
 Protons, 315, 322–324  
 PRS. *See* Photon radiosurgery system
- Q**  
 Quadrantectomy, 36, 42  
 Quality assurance (QA), 151, 153, 155, 156, 167, 169  
   treatment plan, 110–119  
 Quality control, patient positioning, 120–121
- R**  
 Radiation Therapy Oncology Group (RTOG), 5, 11  
   phase II trial 95-17, 221  
 Radiopaque clips, 316  
 Radioprotection, 234, 272, 274  
 Radiotherapy, benefits, 329  
 $\alpha/\beta$  Ratio, 48–51  
 RBE. *See* Relative biologic efficiency  
 Recurrence, 35, 39–43  
   contralateral breast recurrence, 42  
   elsewhere failures, 41–42  
   ipsilateral breast tumor recurrence (IBTR), 40–43  
   patterns, 39–41  
   true recurrence, 42  
 Re-excision studies, 35, 37–41  
 Relative biological effectiveness (RBE), 48  
 Relative biologic efficiency (RBE), 331, 333  
 RTOG 0319, 215, 293  
 RTOG 0413, 296–298
- S**  
 Scar-entry technique (SET), 253–254  
 Seed and soil, 329–330  
 Seed motion, 263, 266–268  
 Selection criteria, 23–30  
   American Brachytherapy Society, 23, 27  
   American Society of Breast Surgeons (ASBS), 23, 27  
 Seroma, 386, 389–391  
 Seroma formation, 259–260  
 Silastic template, 371  
 Single dwell position, 249–252  
 Skin spacing, 253–256, 258–259  
 Strut-adjusted volume implant (SAVI), 29, 62, 68, 87–89, 241–243, 400–402, 404–405, 405  
   preplanning insertion, 241  
 Subcutaneous fibrosis, 380, 383  
 Supine 3D conformal APBI, 277, 278, 294  
   beam arrangements, 289  
   dose volume histograms, 290  
   William Beaumont Hospital experience, 288–293  
 Surgi-Bra, 238  
 Surgical clips, 278, 292, 294–295  
 Surgical margins, 219, 220, 222, 223, 225, 226, 231, 243–245  
 Surgical technique, 402
- T**  
 Target definition, 95  
 Targeted interoperative radiotherapy (TARGIT), 327–340  
   advantages, 333  
   clinical trials, 337–339  
   intrabeam machine and surgical technique, 335–337  
   mathematical model, 332  
   radiobiological aspects, 331–332  
   schematic diagram, 336  
   translational research, 329–330  
   treatment impairments, 330  
   x-ray source, 332–333  
 Target localization, 294  
 Target volume, 220–221, 223–227, 229–231, 237, 239, 244, 245  
 TARGIT. *See* Targeted interoperative radiotherapy  
 Telangiectasias, 166, 258, 260, 273, 380, 382  
 Template technique, 225  
 Template: thick guiding, 235–236  
 Testing a plan for quality and errors, 122–123  
 The Christie Hospital randomized trial,  
 Time, dose, and fractionation (TDF)  
   factor, 268  
 Toxicity endpoints, 379, 385  
 Tracking, catheters, 78  
 Treatment planning, 104–106, 110, 115–117, 120–123, 307, 308, 399–402, 406  
   localization and reconstruction, 104–110  
   CT, 231, 238  
 Trocar, 253–254  
 Tumor-bed boost, 2, 4, 8, 11, 13

- Tumor recurrence  
decreasing age, 213  
ipsilateral breast, 212, 213  
lack of tamoxifen, 213  
local recurrence rate, 212  
regional failure, 212
- U**  
Ultrasound, 74–75, 77–78  
Uniformity indices, 112, 116  
US guidance, 265, 271–272
- V**  
 $\alpha/\beta$  Value, 302, 303  
Venezuela patient, 219–220  
low dose rate (LDR) brachytherapy, 219  
Ochsner Clinic, 219  
soft tissue sarcomas, 219  
Verification  
after needle placement, 103–104  
of the balloon diameter, 104, 108, 118  
of the target, 102–103  
of treatment delivery, 295–296  
Volume check, 118–119
- W**  
Whole breast irradiation (WBI), 20, 27, 30, 153, 154, 159, 160, 219, 221–223  
Whole organ analysis, mastectomy specimens, 328  
William Beaumont Hospital Phase II trial, 221
- X**  
Xoft, 91–93
- Y**  
 $^{90}\text{Y}$ , 428, 429
- Z**  
Zero plane, 269–270